Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | SLC10A2 | Q12908 | 7/20 | 0.40 |
| ▸ | CTSD | P07339 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5225026 | 0.94 | NR1H4 (0.45) | NR1H4SLC10A2CTSDKMT2AATM | |
| SCHEMBL6315240 | 0.90 | SLC10A2 (0.48) | NR1H4SLC10A2KMT2AMEN1PSEN1 | |
| SCHEMBL919390 | 0.89 | NR1H4 (0.59) | NR1H4SLC10A2CTSD | |
| SCHEMBL5224917 | 0.89 | NR1H4 (0.59) | NR1H4SLC10A2CTSD | |
| SCHEMBL14559686 | 0.88 | NR1H4 (0.48) | NR1H4SLC10A2CTSD | |
| SCHEMBL5226757 | 0.87 | SLC10A2 (0.42) | NR1H4SLC10A2PSEN1PSEN2APH1B | |
| SCHEMBL6309108 | 0.86 | SLC10A2 (0.43) | NR1H4SLC10A2PSEN1PSEN2APH1B | |
| Elobixibat SCHEMBL5940599 | 0.86 | NR1H4 (0.59) | NR1H4SLC10A2CTSD | |
| Elobixibat SCHEMBL1183501 | 0.86 | NR1H4 (0.59) | NR1H4SLC10A2CTSD | |
| Elobixibat SCHEMBL5386837 | 0.86 | NR1H4 (0.59) | NR1H4SLC10A2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1345918-B1 | 1,5 BENZOTHIAZEPINES AND THEIR USE AS ANTIHYPERLIPIDEMICS | ASTRAZENECA AB (SE) | 2007-04-18 | — | — | EP | disclosed |
| US-7192945-B2 | Benzothiazepine derivatives | ASTRAZENECA AB (SE) | 2007-03-20 | — | — | US | disclosed |
| US-20040067933-A1 | Chemical compounds | ELOBIX AB (SE) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067933-A1 | Chemical compounds | SLC10A2, SLC10A1, ABCB11 | NR1H4 7/4885SLC10A2 1/4885CTSD 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.